NCT03409276View on ClinicalTrials.gov

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

May 11, 2020

Study Completion Date

October 22, 2020

Conditions
HIV Infections
Interventions
BIOLOGICAL

env (A,B,C,A/E)/gag (C) DNA Vaccine

Administered by intramuscular injection in the deltoid.

BIOLOGICAL

gp120 (A,B,C,A/E) Protein Vaccine

Administered by intramuscular injection in the deltoid.

BIOLOGICAL

Placebo

Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.

BIOLOGICAL

GLA-SE adjuvant

Administered by intramuscular injection in the deltoid.

Trial Locations (6)

14642

University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester

19104

Penn Prevention CRS, Philadelphia

30030

The Hope Clinic of the Emory Vaccine Center CRS, Decatur

35294

Alabama CRS, Birmingham

44106

Case Clinical Research Site, Cleveland

02215-4302

Fenway Health (FH) CRS, Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03409276 - Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults | Biotech Hunter | Biotech Hunter